198 related articles for article (PubMed ID: 37528470)
1. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma.
Kerdivel G; Amrouche F; Calmejane MA; Carallis F; Hamroune J; Hantel C; Bertherat J; Assié G; Boeva V
Clin Epigenetics; 2023 Aug; 15(1):121. PubMed ID: 37528470
[TBL] [Abstract][Full Text] [Related]
2. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
3. Identification of a CpG island methylator phenotype in adrenocortical carcinomas.
Barreau O; Assié G; Wilmot-Roussel H; Ragazzon B; Baudry C; Perlemoine K; René-Corail F; Bertagna X; Dousset B; Hamzaoui N; Tissier F; de Reynies A; Bertherat J
J Clin Endocrinol Metab; 2013 Jan; 98(1):E174-84. PubMed ID: 23093492
[TBL] [Abstract][Full Text] [Related]
4. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma.
Gu P; Zeng Y; Ma W; Zhang W; Liu Y; Guo F; Ruan X; Chi J; Zheng X; Gao M
Front Endocrinol (Lausanne); 2022; 13():1008301. PubMed ID: 36353231
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the etiology and role in oncogenic transformation of the CpG island methylator phenotype: a pan-cancer analysis.
Yates J; Boeva V
Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35134107
[TBL] [Abstract][Full Text] [Related]
7. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
8. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
9. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.
Fu T; Liu Y; Li K; Wan W; Pappou EP; Iacobuzio-Donahue CA; Kerner Z; Baylin SB; Wolfgang CL; Ahuja N
Oncotarget; 2016 Dec; 7(52):86480-86489. PubMed ID: 27880934
[TBL] [Abstract][Full Text] [Related]
10. CpG island methylator phenotype (CIMP) in cancer: causes and implications.
Teodoridis JM; Hardie C; Brown R
Cancer Lett; 2008 Sep; 268(2):177-86. PubMed ID: 18471961
[TBL] [Abstract][Full Text] [Related]
11. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
12. Biological significance of the CpG island methylator phenotype.
Suzuki H; Yamamoto E; Maruyama R; Niinuma T; Kai M
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):35-42. PubMed ID: 25016183
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
Bae JM; Kim JH; Kang GH
Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177
[TBL] [Abstract][Full Text] [Related]
15. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.
Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS
Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
Arai E; Gotoh M; Tian Y; Sakamoto H; Ono M; Matsuda A; Takahashi Y; Miyata S; Totsuka H; Chiku S; Komiyama M; Fujimoto H; Matsumoto K; Yamada T; Yoshida T; Kanai Y
Int J Cancer; 2015 Dec; 137(11):2589-606. PubMed ID: 26061684
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
[TBL] [Abstract][Full Text] [Related]
18. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis.
Liu JB; Zhang YX; Zhou SH; Shi MX; Cai J; Liu Y; Chen KP; Qiang FL
World J Gastroenterol; 2011 Nov; 17(42):4718-24. PubMed ID: 22180715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
